Xenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares

Page 8 of 10

Page 8 of 10 – SEC Filing
 
Partners OS as the general partner of Trading Fund OS may be deemed to beneficially own the 262,664 shares of Common Stock beneficially owned by Trading Fund OS.
 
Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,108,905 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners managed accounts (the “Partners Managed Accounts”), including 610,459 shares of Common Stock held in the Partners Managed Accounts.
 
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,108,905 shares of Common Stock beneficially owned by Partners.
 
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,108,905 shares of Common Stock beneficially owned by BVF Inc.
 
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
 
(b)
Percent of class:
 
The following percentages are based on 17,415,347 shares of Common Stock outstanding, as disclosed in the Issuer’s Prospectus Supplement filed on Form 424B5 with the Securities and Exchange Commission on September 9, 2016.
 
As of the close of business on September 9, 2016 (i) BVF beneficially owned approximately 7.8% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 5.1% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned approximately 1.5% of the outstanding shares of Common Stock (iv) Partners OS may be deemed to beneficially own approximately 1.5% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 17.9% of the outstanding shares of Common Stock (approximately 3.5% of which is held in the Partners Managed Accounts).
 
(c)
Number of shares as to which such person has:
 
(i)
Sole power to vote or to direct the vote
 
See Cover Pages Items 5-9.
 
(ii)
Shared power to vote or to direct the vote
 
See Cover Pages Items 5-9.

Follow Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Page 8 of 10